Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

doi:10.1007/s00345-018-2225-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

World journal of urology - 1 Jun 2018

Hinsch Andrea, Brolund Meta, Hube-Magg Claudia, Kluth Martina, Simon Ronald, Möller-Koop Christina, Sauter Guido, Steurer Stefan, Luebke Andreas, Angerer Alexander, Wittmer Corinna, Neubauer Emily, Göbel Cosima, Büscheck Franziska, Minner Sarah, Wilczak Waldemar, Schlomm Thorsten, Jacobsen Frank, Clauditz Till Sebastian, Krech Till, Tsourlakis Maria Christina, Schroeder Cornelia

Abstract excerpt

BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy. METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation. RESULTS: IDH1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to PTEN Phosphohydrolase

Share to Serine Endopeptidases

Share to Transcriptional Regulator ERG

Source

Open in PubMed

Identifiers

PMID: 29427004
DOI: 10.1007/s00345-018-2225-7

Genes

IDH1
ERG
PTEN
TMPRSS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.PMID 29427004Read ↗

IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.Semantic proximity Read ↗

Highly Recurrent IDH1 Mutations in Prostate Cancer With Psammomatous Calcification.Semantic proximity Read ↗

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.Semantic proximity Read ↗

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.Semantic proximity Read ↗

Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.Semantic proximity Read ↗

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.Semantic proximity Read ↗

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Semantic proximity Read ↗

Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.Semantic proximity Read ↗

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Semantic proximity Read ↗

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.Semantic proximity Read ↗

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.Semantic proximity Read ↗

Monoclonal antibody specific for IDH1 R132H mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.